When a researcher’s name appears in an ORI case summary or a Federal Register “Findings of Research Misconduct” notice, readers often aren’t sure what actually happened. Was this a criminal conviction? A journal decision? An accusation, or a proven finding? This guide walks through what a federal research misconduct finding actually is, how it differs from an institutional finding, what the U.S. Department of Health and Human Services’ Office of Research Integrity (ORI) can and cannot do, and what the resulting sanctions — including debarment — actually mean in practice, illustrated with three recent, verifiable ORI cases spanning the sanction range.
The federal definition of research misconduct
ORI’s authority comes from the Public Health Service (PHS) research misconduct regulation at 42 CFR Part 93, which applies to research conducted or proposed with PHS funding (including NIH and other HHS agencies). Under 93.103, research misconduct means fabrication, falsification, or plagiarism (FFP) in proposing, performing, or reviewing research, or in reporting research results:
- Fabrication — making up data or results and recording or reporting them.
- Falsification — manipulating research materials, equipment, or processes, or changing/omitting data or results, such that the research is not accurately represented in the record.
- Plagiarism — appropriating another person’s ideas, processes, results, or words without giving appropriate credit.
A finding of research misconduct requires all three of the following, per 93.104:
- A significant departure from accepted practices of the relevant research community;
- The misconduct was committed intentionally, knowingly, or recklessly; and
- The allegation is proven by a preponderance of the evidence — meaning more likely than not, the lowest standard of proof in U.S. law, well below the “clear and convincing evidence” or “beyond a reasonable doubt” standards used elsewhere in the legal system.
The regulation is explicit about what does not count. 93.104 states that research misconduct “does not include honest error or differences of opinion.” A miscalibrated instrument, an unintentional transcription error, or a legitimate disagreement over interpretation, methodology, or statistical approach is not misconduct, even if the underlying data or conclusion turns out to be wrong. The intent element is what separates a mistake from a violation — which is also why ORI findings, when they happen, describe conduct as intentional, knowing, or reckless rather than merely “incorrect.”
Institutional finding vs. ORI finding — the distinction readers routinely conflate
Under 42 CFR Part 93, the institution that received the PHS funds — not ORI — has primary responsibility for responding to an allegation. That means most of the actual fact-finding happens at the university, medical center, or research institute level, through a two-stage process: an inquiry (a preliminary assessment of whether the allegation warrants a full investigation) followed, if warranted, by a formal investigation conducted by the institution’s research integrity office.
An institutional finding is the institution’s own conclusion, reached through its own process, under its own federally-mandated policy. It can result in institutional consequences — termination, retraction requests, internal sanctions — entirely independent of ORI. Many misconduct cases never reach ORI’s public record at all because the institution’s finding is the end of the matter, or because the allegation didn’t involve PHS-supported research.
An ORI finding is a separate, federal-level determination. When PHS funding is involved, the institution is required to report its investigation and findings to ORI, which reviews the institutional record, may request additional information or conduct its own inquiry, and independently decides whether the evidence supports a federal finding of research misconduct. ORI can accept the institution’s finding, reject it, or reach a different conclusion on the same facts. Only ORI — not the institution — can impose federal administrative actions such as debarment or PHS advisory-service exclusion, because only ORI has authority over PHS funding and federal procurement/nonprocurement transactions government-wide.
In short: an institutional finding is what your university concluded about your conduct; an ORI finding is what the federal government concluded about your conduct, with federal-level consequences attached. A researcher can have one without the other, and the two records are not always identical. For the full procedural walkthrough of how these two layers interact, see our guide to institutional vs. federal jurisdiction in research misconduct cases.
How an ORI finding actually gets made
The process, set out in 42 CFR Part 93 Subpart B and C, generally runs:
- Allegation. A concern is raised — often by a co-author, lab member, journal editor, or data-integrity forensics work (image-duplication screening is a common trigger in recent cases).
- Institutional inquiry. The institution’s research integrity officer conducts a preliminary review to decide whether a full investigation is warranted, typically within 60 calendar days.
- Institutional investigation. If warranted, a formal investigation committee gathers evidence, interviews witnesses, and reaches findings, generally within 120 days of the investigation’s start (extensions are common and must be reported to ORI).
- Report to ORI. The institution submits its investigation report and supporting evidence to ORI for review.
- ORI review and charge letter. ORI’s Division of Investigative Oversight reviews the record and, if it concurs that misconduct occurred, issues a charge letter proposing findings and administrative actions to the respondent.
- Respondent’s right to a hearing. The respondent can accept the findings, negotiate a settlement (a voluntary exclusion agreement, in which a respondent accepts sanctions without a formal admission or contest), or request a hearing before an Administrative Law Judge (ALJ) at HHS’s Departmental Appeals Board.
- Final HHS decision. If a hearing is requested and the ALJ upholds the findings, the case goes to the HHS Secretary’s Designated Official for a final agency decision, which is what actually triggers published administrative actions such as debarment.
Respondents have real procedural rights throughout this process, including notice of the allegations, access to the evidence, and the opportunity to respond before any finding becomes final — covered in detail in our guide to respondent rights during an ORI investigation. For the administrative mechanics of each stage, see how a research misconduct investigation actually works.
What sanctions ORI can impose, and the real range they span
Under 42 CFR 93.407, ORI’s available administrative actions include (from least to most severe): a letter of reprimand; required correction of the research record (retractions or corrections to affected publications); certification or supervision of the respondent’s future PHS-supported research for a set period; special award conditions on future grants; probation; suspension; exclusion from serving on PHS advisory committees, boards, or peer review panels; and debarment from participating in federal “covered transactions” for a set number of years.
These aren’t applied uniformly — sanction severity tracks the scope and persistence of the misconduct found. Three recent, publicly documented ORI cases illustrate the actual range:
- Daniel Andrade, PhD (formerly University of Oklahoma Health Sciences Center): ORI found Andrade intentionally falsified and/or fabricated data in two NIH grant applications — relabeling data from a cell line as data from patient-derived organoids, and splicing together western blot images from unrelated experiments. No published papers were implicated. ORI’s sanction: a three-year period of supervision for federally funded research and a three-year PHS advisory-service exclusion, both under 42 CFR 93.407. Andrade did not contest the findings. ORI case summary.
- Chen-Yeh “George” Ke, PhD (former postdoctoral fellow, Icahn School of Medicine at Mount Sinai): ORI found Ke falsified and/or fabricated western blot data by reusing and relabeling blot images to represent different experiments, affecting one unpublished manuscript and two NIH progress reports. ORI’s sanction: a three-year supervision period plus a PHS advisory-service ban. Ke did not contest the findings. ORI case summary.
- Ariel Fernandez, PhD (former Karl F. Hasselmann Chaired Professor of Engineering, Rice University): ORI found Fernandez intentionally, knowingly, or recklessly fabricated and/or falsified research across 12 peer-reviewed published papers, four unpublished manuscripts, one presentation, and three NIH grant applications — including fabricated chemical compounds and roughly two dozen falsified western blot and microscopy figures. ORI’s sanctions: a 15-year PHS advisory-service exclusion beginning June 22, 2025, and a 15-year debarment from federal covered transactions beginning March 25, 2026 — among the longest debarment periods ORI has imposed. Fernandez contested the findings before an Administrative Law Judge, who granted summary judgment for HHS; the final debarment notice followed. ORI case summary | Federal Register notice.
The contrast is instructive. Andrade and Ke’s cases involved unpublished or application-stage material, were not contested, and drew supervision-level sanctions with no debarment. Fernandez’s case involved fabrication across a dozen published papers over an extended period, was contested through a full administrative hearing, and drew the most severe sanction ORI imposes. Sanction severity in ORI cases generally scales with the volume and persistence of the fabricated/falsified record, whether the case reached the published literature, and whether the respondent contested the findings. For more closed, citable cases across this range, see our research misconduct case studies guide, and for the fuller menu of consequences beyond ORI’s own sanctions — retraction, SAM.gov exclusion, False Claims Act exposure — see the consequences of research misconduct.
What debarment actually means, in practice
Debarment is the most severe sanction ORI can impose, and it is frequently misunderstood as narrower than it is. A debarred individual is excluded from participating in “covered transactions” under the federal debarment and suspension system (2 CFR Part 180 for nonprocurement transactions like grants and cooperative agreements, and the parallel Federal Acquisition Regulation system for procurement contracts). In practice, for the length of the debarment period, that means the individual:
- Cannot receive a new federal grant, cooperative agreement, or contract as principal investigator or key personnel from any federal agency — not just the one that funded the misconduct-affected research, because the FAR and nonprocurement debarment systems are reciprocal.
- Cannot serve as a subrecipient, subcontractor, or consultant on a federally funded project above the covered-transaction threshold without the funding institution obtaining special agency approval.
- Is listed on the SAM.gov Exclusions list, which institutions are required to check before entering into new federally funded arrangements — see our explainer on debarment and suspension verification via SAM.gov.
Because most biomedical and life-sciences research in the U.S. runs on federal funding, a multi-year debarment can effectively end a researcher’s ability to lead federally funded work for its duration, even at an institution willing to continue employing them. Debarment does not, by itself, revoke a degree, a medical or professional license, or bring criminal charges — those are separate processes (institutional, state licensing board, or Department of Justice, respectively) that may or may not follow an ORI finding depending on the facts of the case.
What appears in the public record
Three things typically become public once an ORI finding is finalized:
- ORI’s own case summary, published at ori.hhs.gov/case_summary. Note that this list only includes cases with a currently active administrative action, organized by year closed — it is not a complete historical archive, and cases whose sanction period has fully expired eventually drop off the public list.
- A Federal Register notice titled “Findings of Research Misconduct,” published by HHS, which is the formal legal notice of the administrative action.
- Corrections or retractions to any affected publications, which ORI’s finding typically directs the respondent (or the institution) to request from the relevant journals.
What does not automatically become public: the institutional inquiry and investigation reports themselves (these are generally confidential, though may be released under FOIA in redacted form or become public through litigation), and any case that concludes at the institutional level without being referred to, or substantiated by, ORI.
Frequently asked questions
Does an ORI finding mean the researcher committed a crime?
Not by itself. Research misconduct findings under 42 CFR Part 93 are administrative, not criminal, and use the preponderance-of-the-evidence standard rather than a criminal burden of proof. Some misconduct cases do lead to separate criminal or civil proceedings (for example, under the False Claims Act, where federal grant funds were obtained through fabricated data), but that requires independent action by the Department of Justice, not ORI.
Can a researcher contest an ORI finding?
Yes. A respondent who receives an ORI charge letter can request a hearing before an Administrative Law Judge at HHS’s Departmental Appeals Board, as Ariel Fernandez did. The ALJ can grant summary judgment for either side or proceed to a full hearing; the ALJ’s recommended decision goes to the HHS Secretary’s Designated Official, whose decision is final.
Is a Voluntary Exclusion Agreement the same as an ORI finding of misconduct?
No, and this is a common point of confusion. A Voluntary Exclusion Agreement lets a respondent accept administrative actions (such as a supervision period or advisory-service ban) without ORI making a formal finding of research misconduct and without the respondent admitting wrongdoing. See our explainer on voluntary exclusion agreements for how this differs from a contested or accepted finding.
Is honest error ever prosecuted as research misconduct?
No. 42 CFR 93.104 explicitly excludes honest error and honest differences of opinion from the definition of research misconduct. ORI’s three-part test requires intent (intentional, knowing, or reckless conduct) as well as a significant departure from accepted practice — an unintentional mistake, however consequential, does not meet that bar. See our dictionary entry on research misconduct for the operational definition and worked examples of the fabrication/falsification/plagiarism boundary.
Does an ORI finding apply only to research funded by NIH?
ORI’s jurisdiction covers research supported by Public Health Service funds, which includes NIH but also other HHS agencies such as the CDC, FDA, and AHRQ. Research funded by non-PHS federal agencies (NSF, DOE, etc.) has its own, separate misconduct-review processes and is not within ORI’s jurisdiction, though those agencies’ processes follow a broadly similar inquiry/investigation structure.
This guide is not legal advice. If you are involved in an active ORI matter, consult your institution’s research integrity office or independent legal counsel.
